ArticleCureus2026

Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System.

Alisher Makhmutov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.